Related references
Note: Only part of the references are listed.Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases
Michel Gallant et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Pharmacological Characterization of MK-7246, a Potent and Selective CRTH2 (Chemoattractant Receptor-Homologous Molecule Expressed on T-Helper Type 2 Cells) Antagonist
Francois G. Gervais et al.
MOLECULAR PHARMACOLOGY (2011)
Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion
Xi He et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Characterization of UGTs Active against SAHA and Association between SAHA Glucuronidation Activity Phenotype with UGT Genotype
Renee M. Balliet et al.
CANCER RESEARCH (2009)
Determination of mRNA Expression of Human UDP-Glucuronosyltransferases and Application for Localization in Various Human Tissues by Real-Time Reverse Transcriptase-Polymerase Chain Reaction
Shuji Ohno et al.
DRUG METABOLISM AND DISPOSITION (2009)
A Common Deletion in the Uridine Diphosphate Glucuronyltransferase (UGT) 2B17 Gene Is a Strong Determinant of Androgen Excretion in Healthy Pubertal Boys
A. Juul et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Interindividual Variability in Pharmacokinetics of Generic Nucleoside Reverse Transcriptase Inhibitors in TB/HIV-Coinfected Ghanaian Patients: UGT2B7*1c Is Associated With Faster Zidovudine Clearance and Glucuronidation
Awewura Kwara et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Doping test results dependent on genotype of uridine diphospho-glucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation
Jenny Jakobsson Schulze et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men
Jong Park et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2006)
Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism
J Jakobsson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
A UGT2B17-positive donor is a risk factor for higher transplant-related mortality and lower survival after bone marrow transplantation
S Terakura et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Polymorphism of UDP-glucuronosyltransferase and drug metabolism
Y Maruo et al.
CURRENT DRUG METABOLISM (2005)
Drug-drug interactions for UDP-glucuronosyltransferase substrates:: A pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios
JA Williams et al.
DRUG METABOLISM AND DISPOSITION (2004)
Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15
W Wilson et al.
GENOMICS (2004)
Glucuronidation activity of the UGT2B17 enzyme toward xenobiotics
D Turgeon et al.
DRUG METABOLISM AND DISPOSITION (2003)
Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan
Y Ando et al.
THERAPEUTIC DRUG MONITORING (2002)
Share Paper
